Teva announces priority review granted by FDA for SD-809 for treatment of tardive dyskinesia

16th March 2017 Uncategorised 0

Teva Pharmaceutical Industries

More: Teva announces priority review granted by FDA for SD-809 for treatment of tardive dyskinesia
Source: MDlinx